J&J
Johnson & Johnson posts strong Q3 results
October 16, 2013Sales and Marketing J&J, JJ, Q3, Velcade, results
Johnson & Johnson has posted a strong set of financials for the third quarter as new products from its pharma …
J&J partners with European biotech firms
October 4, 2013Research and Development, Sales and Marketing J&J, JJ, effimune, life sciences, merus
The London Johnson & Johnson Innovation Centre has teamed up with several biotech partners from the European region. Announced at …
J&J’s prescription drugs unit hit by recall
September 17, 2013Manufacturing and Production J&J, JJ, Risperdal, Tylenol, recalls
J&J’s manufacturing recovery hits a hurdle
September 10, 2013Manufacturing and Production API, J&J, JJ, McNeil, Motrin, recall
Johnson & Johnson’s path back to regulatory compliance in its manufacturing operations has hit another snag after the firm was …
J&J says revived OTC brands are ‘winning the hearts of consumers’
July 19, 2013Manufacturing and Production, Sales and Marketing Control, FDA, GDP, J&J, JJ, OTC
Johnson & Johnson doesn’t usually provide specific financials for its over-the-counter pharmaceuticals business, but did so for the first time …
J&J sees Q2 sales rise
July 17, 2013Sales and Marketing Elan, J&J, JJ, Q2, Synthes, sales
Johnson & Johnson saw overall sales rise 8.5% year-on-year in the second quarter of 2013, with the US healthcare group …
Next generation digital firms for Europe wanted
July 15, 2013Medical Communications, Sales and Marketing J&J, JJ, digital, innovation
Digital health start-ups from across Europe are being called on to form a part of Johnson & Johnson Innovation’s inaugural …
J&J opens office at Stevenage Bioscience Catalyst
June 21, 2013Manufacturing and Production, Research and Development J&J, JJ, bioscience, catalyst
Johnson & Johnson Innovation has establishment a partnering office at Stevenage Bioscience Catalyst to support emerging entrepreneurs and biotech firms …
J&J to pay up to $1 billion in Aragon deal
June 18, 2013Research and Development, Sales and Marketing Aragon, J&J, JJ, Zytiga
Johnson & Johnson could pay as much as $1 billion to buy prostate cancer specialist Aragon Pharmaceuticals. The acquisition includes …
J&J recalls 32 million contraceptive packs
June 5, 2013Manufacturing and Production Cilest, J&J, JJ, recall
Johnson & Johnson has announced a 43-country recall of its oral contraceptive Cilest and suspended production of the drug because …
South Korea eyeing criminal charges over J&J plant failures
May 17, 2013Manufacturing and Production J&J, JJ, Janssen, Korea, MFDS
The chief executive of Johnson & Johnson’s South Korean subsidiary could be facing criminal charges over quality lapses at a …
Asian regulators take issue with J&J facilities
May 7, 2013Manufacturing and Production India, J&J, JJ, Korea, inspection
Johnson & Johnson’s manufacturing network is under yet more scrutiny following regulatory actions by authorities in India and South Korea. …
J&J sees OTC recovery in Q1
April 23, 2013Manufacturing and Production J&J, JJ, manufacturing issues, recall
Johnson & Johnson is moving steadily closer to a sustained recovery in its McNeil Consumer Healthcare division as the manufacturing …
J&J opens London hub
March 14, 2013Medical Communications, Research and Development, Sales and Marketing J&J, JJ, London, research
Johnson & Johnson has opened the doors to a new life sciences centre in London that forms part of a …
Pharma manufacturing news in brief
March 11, 2013Business Services, Manufacturing and Production Actavis, DSM, Eisai, J&J, JJ, Marken, SAFC, Sagent Pharma
Actavis revises supply deal with Sagent, facility updates from Marken and SAFC, a supply deal for DSM plus another J&J …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
